Fig. 7

In vivo biological behaviors and therapeutic efficacy of 2D PEG/Cu-BDC nanocatalysts on 4T1 tumor-bearing mice. a In vivo pharmacokinetic profile of PEG/Cu-BDC (n = 3 biologically independent samples). b The biodistribution of PEG/Cu-BDC in tumor tissues and major organs (heart, liver, lung, spleen, and kidney) at different durations post-injection (4, 8, and 24 h) (n = 3 biologically independent samples). c Body weight variations, d relative tumor volumes, e tumor growth rates, and f tumor inhibition rates of the mice in different treatment groups (P values: *P < 0.05, **P < 0.01, and ***P < 0.001). g H&E, TUNEL, and Ki-67 staining of tumor sections (Scale bar: 100 μm), and h H&E staining of the major organs in different treatment groups (Scale bar: 100 μm)